September 2, 2014     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
News Sectors
Health & Med
IT & Internet
Real Estate
Science & Research
Annual Reports
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
Terms of Use
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Seoul, Nov 23, 2010 - (ACN Newswire) - Suprema, Inc., a global leader in biometrics and ID solutions, announced today that the company's RealScan-F palm-print live scanner has been selected for the AFIS systems of the Polish National Police and Lithuania's Citizenship & Migration Affairs.   [ more... ]

 Headline News

Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Yokogawa Electric announced that its confocal image single-cell drug discovery support system has been selected for the Japan Science and Technology Agency's (JST) next-generation technology transfer program (NexTEP). more info >>
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Sysmex Corporation and Toppan Printing Co., Ltd. are to cooperate for the advancement in the genetic analysis testing industry, and to invest in RIKEN GENESIS Co., Ltd., a Toppan Printing subsidiary. more info >>
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Takara Bio Inc. has submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) dated April 30, 2014 in order to conduct a phase II clinical trial in the United States of the oncolytic virus HF10 in patients with unresected or metastatic malignant melanoma. more info >>
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Nitto Denko Corporation has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof. Yoshiro Niitsu of Sapporo Medical University. more info >>
ACN Newswire
 Press Release News

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)
Eisai Co., Ltd. announced today that it has submitted applications to regulatory authorities in the U.S. and Europe (the FDA and EMA respectively) for the indication expansion of its in-house developed antiepileptic drug Fycompa as an adjunctive treatment of primary generalized tonic-clonic seizures (PGTC). more info >>
Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)
Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai. more info >>
University of Tokyo's RCAST, Fujitsu, and Kowa Successfully Generate a Novel Active Compound Targeting Cancer Using IT-based Drug Discovery Technology (Aug 7, 2014)
The University of Tokyo's Research Center for Advanced Science and Technology (RCAST), Fujitsu Limited, and Kowa Company, Ltd. today announced that they have used IT-based drug discovery technology to successfully generate a novel pharmacologically active compound with the potential to be developed into a candidate for an anticancer drug. more info >>
Eisai Supports Earthquake Relief Efforts in Yunnan, China (Aug 7, 2014)
Eisai expresses its heartfelt sympathies to all those affected by the recent earthquake which occurred in Ludian county of Zhaotong city, Yunnan province, China. more info >>
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment (July 31, 2014)
Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency (EMA) for its in-house developed anticancer agent lenvatinib mesylate in the treatment of radioiodine-refractory differentiated thyroid cancer. more info >>
 Global Press Release

Understanding and Improving the Body's Fight Against Pathogens (Sept 1, 2014)

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)

Novel Gene Predicts Both Breast Cancer Relapse and Response to Chemotherapy (Aug 20, 2014)

Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)

Carbon Nanotubes and Near-infrared Lasers Promise a Cost Effective Solution for Cell Membrane Manipulation (Aug 15, 2014)

 ::: Listed Health & Pharm Companies
 Biotechnology  Healthcare
 Medical Products  Pharmaceutical
JCN Network - Company Profiles - Company Listing
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)